-
公开(公告)号：US20110294861A1
公开(公告)日：2011-12-01
申请号：US13205164
申请日：2011-08-08
IPC分类号： A61K31/4196 , A61P3/00
CPC分类号： A61K31/4196
摘要： The present invention relates to the use of Compound I of the following formula in the treatment of iron overload resulting from hereditary hemochromatosis in patient in need of such a treatment and to a commercial package comprising Compound I together with instructions for the treatment of iron overload in hereditary hemochromatosis patients.
-
2.发明申请Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia 审中-公开因子VII多肽用于预防血友病患者形成抑制剂公开(公告)号：US20050032690A1
公开(公告)日：2005-02-10
申请号：US10737936
申请日：2003-12-17
申请人： Lisa Rojkjaer , Marie Johannessen , Ole Nordfang , Jens Jansen
发明人： Lisa Rojkjaer , Marie Johannessen , Ole Nordfang , Jens Jansen
CPC分类号： A61K38/4846 , A01K2217/05 , C12N9/6437 , C12Y304/21021 , A61K2300/00
摘要： The invention provides a method for preventing formation of inhibitors to blood coagulation factor VIII or factor IX in a subject having haemophilia, the method comprising administering (via intravenous, subcutaneous, intradermal, or intramuscular routes) to a previously untreated subject an effective dosage of factor VIIa or a factor VII-related polypeptide.
摘要翻译： 本发明提供了一种防止在具有血友病的受试者中形成血液凝固因子VIII或因子IX的抑制剂的方法，所述方法包括向先前未经治疗的受试者施用（通过静脉内，皮下，皮内或肌内途径）有效剂量的因子 VIIa或VII因子相关多肽。
-
3.发明授权Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL 有权抗CD38抗体和来那度胺或硼替佐米用于治疗多发性骨髓瘤和NHL公开(公告)号：US08877899B2
公开(公告)日：2014-11-04
申请号：US13825325
申请日：2011-09-26
IPC分类号： A61K39/395 , C07K16/28 , C07K16/30 , A61K31/69 , A61K45/06 , A61K38/07 , A61K38/05 , A61K31/454 , A61K39/00
CPC分类号： C07K16/40 , A61K31/454 , A61K31/69 , A61K38/05 , A61K38/07 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K16/2896 , C07K16/3061 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/76 , A61K2300/00
摘要： The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.
摘要翻译： 本公开描述了抗CD38抗体和来那度胺的药物组合以及抗CD38抗体和硼替佐米的药物组合。
-
4.发明申请公开(公告)号：US20140227277A1
公开(公告)日：2014-08-14
申请号：US14127217
申请日：2012-08-14
IPC分类号： A61K31/7076 , C07K16/28
CPC分类号： A61K31/7076 , A61K2039/505 , C07K16/2803
摘要： The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a purine analog for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
摘要翻译： 本公开描述了用于治疗非霍奇金淋巴瘤，慢性淋巴细胞白血病和/或急性成淋巴细胞性白血病的抗CD19抗体和嘌呤类似物的药物组合。
-
公开(公告)号：US20110105575A1
公开(公告)日：2011-05-05
申请号：US12301777
申请日：2007-05-21
IPC分类号： A61K31/4196 , A61P3/00
CPC分类号： A61K31/4196
摘要： The present invention relates to the use of Compound I of the following formula in the treatment of iron overload resulting from hereditary hemochromatosis in patient in need of such a treatment and to a commercial package comprising Compound I together with instructions for the treatment of iron overload in hereditary hemochromatosis patients.
摘要翻译： 本发明涉及下列化学式I化合物在治疗由需要这种治疗的患者遗传性血色素沉着症引起的铁超负荷以及包含化合物I的商业包装以及用于治疗铁过载的说明书中的用途 遗传性血色素沉着病患者。
-
6.发明申请COMBINATION THERAPY WITH AN ANTI - CD19 ANTIBODY AND A NITROGEN MUSTARD 审中-公开联合治疗与抗原 - CD19抗体和NITROGEN MUSTARD公开(公告)号：US20140255427A1
公开(公告)日：2014-09-11
申请号：US14126928
申请日：2012-08-14
IPC分类号： A61K39/395 , A61K31/4184
CPC分类号： A61K39/3955 , A61K31/4184 , A61K39/39558 , A61K2039/505 , C07K16/2803 , C07K16/30 , A61K2300/00
摘要： The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a nitrogen mustard for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
摘要翻译： 本公开描述了用于治疗非霍奇金淋巴瘤，慢性淋巴细胞性白血病和/或急性成淋巴细胞白血病的抗CD19抗体和氮芥的药物组合。
-
7.发明申请Anti-CD38 Antibody and Lenalidomide or Bortezomib for the Treatment of Multipe Myeloma and NHL 有权抗CD38抗体和来那度胺或硼替佐米用于治疗多发性骨髓瘤和NHL公开(公告)号：US20130302318A1
公开(公告)日：2013-11-14
申请号：US13825325
申请日：2011-09-26
IPC分类号： A61K39/395 , A61K31/69 , A61K38/07 , A61K31/454
CPC分类号： C07K16/40 , A61K31/454 , A61K31/69 , A61K38/05 , A61K38/07 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K16/2896 , C07K16/3061 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/76 , A61K2300/00
摘要： The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.
摘要翻译： 本公开描述了抗CD38抗体和来那度胺的药物组合以及抗CD38抗体和硼替佐米的药物组合。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.017 秒)
